Insider Selling: Teva Pharmaceutical Industries Limited (NYSE:TEVA) Director Sells 286,000 Shares of Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $22.77 on Friday. The firm has a fifty day simple moving average of $18.25 and a two-hundred day simple moving average of $17.72. Teva Pharmaceutical Industries Limited has a twelve month low of $10.39 and a twelve month high of $22.80. The company has a market capitalization of $25.80 billion, a PE ratio of -26.79, a P/E/G ratio of 0.99 and a beta of 0.79. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently bought and sold shares of the stock. UMB Bank n.a. lifted its position in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares during the last quarter. Smithfield Trust Co increased its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $50,000. Claro Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $52,000. Finally, Mark Sheptoff Financial Planning LLC bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth $57,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TEVA has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, UBS Group increased their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.